Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits

Abstract excerpt

Overexpression of Dual-specificity tyrosine-phosphorylated regulated kinase 1A (DYRK1A), located on human chromosome 21, may alter molecular processes linked to developmental deficits in Down syndrome (DS). Trisomic DYRK1A is a rational therapeutic target, and although reductions in Dyrk1a genetic dosage have shown improvements in trisomic mouse models, attempts to reduce Dyrk1a activity by pharmacological...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Down syndrome and intellectual disability research
• Share to Genetics and Neurodevelopmental Disorders
• Share to Genomic variations and chromosomal abnormalities